（编辑 李家琪） 证券日报网讯 9月2日晚间，迈威生物发布公告称，公司股票于2025年8月29日、9月1日和9月2日连续三 个交易日内日收盘价格涨幅偏离值累计超过30%，属于股票交易异常波动情形。经公司自查并向控股股 东、实际控制人及其一致行动人书面发函查证，确认不存在应披露而未披露的重大事项或重要信息。公 司股价短期波动幅度较大，敬请广大投资者注意市场交易风险，审慎决策，理性投资。 ...

Core Viewpoint - Maiwei Biotech has re-submitted its application for H-share issuance and listing on the Hong Kong Stock Exchange, marking its second attempt after an initial application in January 2025. The company is facing significant financial pressure due to ongoing losses and a governance crisis involving its chairman [2][10]. Company Overview - Founded in 2017, Maiwei Biotech specializes in the research, production, and sales of therapeutic biological products, primarily focusing on antibody and recombinant protein drugs. The company has 14 key products in various stages of clinical development, including 10 innovative drugs and 4 biosimilars, targeting cancer and age-related diseases [4][5]. Financial Performance - Since its listing on the Sci-Tech Innovation Board in early 2022, Maiwei Biotech has raised 3.3 billion yuan but has incurred cumulative losses exceeding 3.5 billion yuan. As of mid-2025, total losses since the company's inception have reached 6.27 billion yuan. The company's operating capital is heavily reliant on external financing, with a current debt level of 77% [4][5]. Research and Development Investment - The company has maintained high R&D expenditures, with investments of 759 million yuan, 836 million yuan, and 783 million yuan from 2022 to 2024, and 392 million yuan in the first half of 2025, representing a 21.72% increase year-on-year. R&D spending accounted for 387.57% of operating income, up 108.74 percentage points year-on-year [5]. Sales Performance - Despite having four products approved for commercialization, sales performance has been disappointing. For instance, sales of the core product Junmaikang (an adalimumab biosimilar) fell by 66.61% in 2024, generating only 31.6 million yuan. Other products like Mailishu and Maiweijian also reported low sales figures [6][8]. Governance Issues - The company is facing governance challenges, particularly following the investigation of its chairman, Liu Datao, for suspected insider trading. This situation raises concerns about the company's reputation and future development [8][10]. Financing Needs - Given the ongoing financial losses and governance issues, Maiwei Biotech views its Hong Kong listing as a critical opportunity to alleviate liquidity pressures. The company has re-applied for listing after its initial application expired due to regulatory delays [10]. Potential Breakthroughs - A key product for the company is the 9MW3811 injection, aimed at treating pathological scars and targeting anti-aging. The company is the first in China to develop an IL-11 antibody drug, with clinical trials expected to start by the end of the year. A licensing agreement with Calico, a leader in anti-aging research, has been established for this drug [11].

Summary of Key Points Core Viewpoint - On September 2, a total of 40 stocks were identified with institutional activity, with 19 stocks showing net buying and 21 stocks showing net selling by institutions [1]. Institutional Buying - The top three stocks with the highest net buying by institutions were: - Liao Co., with a net buying amount of 222 million [1] - Maiwei Bio, with a net buying amount of 109 million [1] - Yingweike, with a net buying amount of 93.3 million [1]. Institutional Selling - The top three stocks with the highest net selling by institutions were: - Baiji Shenzhou, with a net outflow amount of 1.261 billion [1] - Jingwang Electronics, with a net outflow amount of 290 million [1] - Chuangxin Medical, with a net outflow amount of 216 million [1].

Group 1 - Institutional trading today featured 36 stocks, with 17 seeing net buying and 19 experiencing net selling [1] - The top three stocks with the highest institutional buying were: Liao Group (2.22 billion), Maiwei Bio (1.09 billion), and Yingweike (932.9 million) [1] - Liao Group's closing price on September 2 was 5.85 yuan, categorized as a low-priced stock [3] Group 2 - Liao Group's board approved a plan to use up to 3 billion yuan of its own funds for securities investment [3] - A leading robotics company reportedly had a meeting with Tesla, which provided optimistic production guidance for next year, indicating a potential weekly production of 10,000 units by Q3 [3] - The National Standardization Administration and the Ministry of Industry and Information Technology released a plan for establishing a high-quality standard system for industrial mother machines by 2026 [3]

证券代码：688062 证券简称：迈威生物 公告编号：2025-050 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 迈威（上海）生物科技股份有限公司（以下简称"公司"）股票于 2025 年 8 月 29 日、9 月 1 日和 9 月 2 日连续三个交易日内日收盘价格涨幅偏离值累 计超过 30%。根据《上海证券交易所交易规则》《上海证券交易所科创板股票异 常交易实时监控细则》的有关规定，属于股票交易异常波动情形。 经公司自查并书面发函向控股股东、实际控制人及其一致行动人书面核 实，截至本公告披露日，确认不存在应披露而未披露的重大事项或重要信息。 公司股价短期波动幅度较大，敬请广大投资者注意市场交易风险，审慎 决策，理性投资。 一、股票交易异常波动的具体情况 公司股票于 2025 年 8 月 29 日、9 月 1 日和 9 月 2 日连续三个交易日内日收 盘价格涨幅偏离值累计超过 30%，根据《上海证券交易所交易规则》《上海证券 交易所科创板股票异常交易实时监控细则》的有关规定，属于股票交易异常波动 情形。 ...

Core Viewpoint - Maiwei Biotech (688062.SH) reported a decline in revenue and increased losses in its 2025 semi-annual report, indicating ongoing financial challenges for the company [1][3][4]. Financial Performance - The company achieved a revenue of 101.17 million yuan in the first half of 2025, a year-on-year decrease of 12.43% [1][3]. - The net profit attributable to shareholders was -551.32 million yuan, compared to -444.98 million yuan in the same period last year [1][3]. - The net profit excluding non-recurring items was -573.54 million yuan, worsening from -460.73 million yuan year-on-year [1][3]. - The net cash flow from operating activities was -33.92 million yuan, an improvement from -461.62 million yuan in the previous year [1][3]. Historical Performance - Maiwei Biotech has reported losses for eight consecutive years, with net profits attributable to shareholders from 2017 to 2024 being -1.03 billion yuan, -2.25 billion yuan, -9.28 billion yuan, -6.43 billion yuan, -7.70 billion yuan, -9.55 billion yuan, and -10.53 billion yuan respectively [4]. Capital Raising and Listing - The company submitted a new application for H-share issuance and listing on the Hong Kong Stock Exchange on August 31, 2025 [4]. - Maiwei Biotech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 18, 2022, raising a total of 3.477 billion yuan, exceeding its initial fundraising target by 323 million yuan [4][5]. - The funds raised are intended for the construction of a 1000kg antibody production project, antibody drug research and development, and to supplement working capital [4].

Core Viewpoint - Maiwei Biotech is facing significant financial challenges, including high debt levels and continuous losses, prompting the company to reapply for an IPO in Hong Kong to secure funding for sustainable development and international expansion [1][2][3]. Financial Performance - As of mid-2025, the company's debt-to-asset ratio reached a record high of 77.54%, indicating increasing financial strain [5]. - Cumulative revenue over 8.5 years is approximately 550 million yuan, while net losses total around 6.27 billion yuan [11]. - The company reported a revenue decline of 12.43% year-on-year for the first half of 2025, with a net loss of 551 million yuan, a 23.90% decrease compared to the previous year [9]. Research and Development Investment - Maiwei Biotech has invested heavily in R&D, with total R&D expenses amounting to 4.613 billion yuan over 8.5 years [12][17]. - R&D expenses for the first half of 2025 reached 392 million yuan, representing a 21.72% increase year-on-year, nearly four times the revenue for the same period [16]. - The company has a significant workforce dedicated to R&D, with 27.83% of its 1,362 employees engaged in this area [17]. IPO and Funding Strategy - The company has reapplied for an H-share listing on the Hong Kong Stock Exchange to meet operational funding needs and enhance international presence [1][3]. - In addition to the IPO, Maiwei Biotech plans to issue up to 500 million yuan in debt financing tools and seek credit lines totaling up to 6.2 billion yuan to support its operations and projects [5].

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Insights - 9MW3811, an IL-11 monoclonal antibody developed by the company, is leading globally in clinical progress and has received clinical access in China, the US, and Australia, with completed Phase I trials showing good safety [2][17] - The company has licensed global development and commercialization rights for 9MW3811 (excluding Greater China) to Calico Life Sciences, receiving a non-refundable upfront payment of $25 million and potential milestone payments up to $571 million [2][36] - The market potential for treating pathological scars, including hypertrophic scars and keloids, is significant, with the US market projected to grow from $10.3 billion in 2020 to $12.3 billion in 2025, and further to $18.6 billion by 2030 [40][44] Summary by Sections 1. 9MW3811: Targeting Fibrosis and Aging - 9MW3811 effectively blocks the IL-11/IL-11Ra signaling pathway, addressing unmet needs in fibrosis and aging [2][3] - The mechanism of action for 9MW3811 is well-defined, targeting key aging markers and potentially improving metabolic function and chronic inflammation [3][18] - The product is positioned to address the urgent clinical needs in the pathological scar market, with a projected market size of $5.9 billion in China by 2030 [3][40] 2. Multiple Promising Pipeline Products - 9MW1911, a ST2 monoclonal antibody for COPD, is in Phase Ib/IIa trials with all 80 patients enrolled, aiming for efficacy data by the end of 2025 [4][49] - 9MW2821, a Nectin-4 ADC, is leading globally in clinical progress with promising efficacy data across multiple cancer types, including bladder and triple-negative breast cancer [4][55] - The company is developing additional ADCs and TCE platforms, enhancing its pipeline diversity and potential market impact [4][49] 3. Earnings Forecast and Investment Rating - The revenue forecast for 2025-2027 is maintained at approximately $1.11 billion, $1.24 billion, and $2.09 billion respectively, excluding unrecognized business development payments [5] - The report emphasizes the strong potential of the company's pipeline and maintains a "Buy" rating based on these projections [5]

Group 1 - The closing price of Maiwei Biotech (688062) on September 1 was 57.60 yuan, reaching the daily limit with a trading volume of 1.496 billion yuan and a turnover rate of 12.96% [2] - The stock was listed on the daily trading list due to a price increase of 15% at the close [2] - The top five trading departments accounted for a total transaction of 555 million yuan, with a net buying amount of 87.24 million yuan [2] Group 2 - The main buying department included the Shanghai-Hong Kong Stock Connect, which had a buying amount of 178.71 million yuan, while the main selling department was also the Shanghai-Hong Kong Stock Connect with a selling amount of 91.63 million yuan [3] - Overall, the stock experienced a net outflow of 6.60 million yuan in main funds throughout the day [3] - Specific buying amounts from other departments included 48.45 million yuan from Guotai Junan Securities and 33.64 million yuan from an institutional special seat [3]

Core Viewpoint - Maiwei Biotech has re-submitted its application for H-share issuance and listing in Hong Kong, leading to a significant stock price increase of 20% on September 1, 2023, with a cumulative increase of 65.52% since its listing, resulting in a market capitalization of 23.017 billion yuan [1] Group 1: Company Overview - Established in 2017, Maiwei Biotech is an innovative biopharmaceutical company focusing on oncology and age-related diseases, with four commercialized products as of now [2] - The company has a pipeline of over ten products in various stages of clinical development [2] Group 2: Financial Performance - Despite high R&D investments, the company has incurred cumulative losses of 6.2714 billion yuan since its inception, with over 3.6 billion yuan in losses from 2022 to mid-2025 [3] - Revenue from 2022 to mid-2025 was only 457 million yuan, with a 12.43% year-on-year decline in revenue for the first half of 2023 [3] - The company reported a net profit attributable to shareholders of -552 million yuan for the first half of 2023 [3] Group 3: Market Competition - Maiwei Biotech faces intense competition in the market for its biosimilar products, particularly the adalimumab biosimilar, which saw a 66.61% decline in shipments in 2024 [4] - The company is also experiencing slow market access for its other biosimilar products, indicating a lack of competitive advantage [5] Group 4: Funding and Financial Strategy - The company relies heavily on external financing for operations, with a significant increase in debt ratio from 42.24% in 2023 to 77.54% in mid-2025 [7] - To address cash flow issues, the company plans to diversify its financing channels and maintain a high leverage ratio to support ongoing R&D investments [8] - Maiwei Biotech has also proposed to issue up to 500 million yuan in targeted debt financing tools to optimize its debt structure and reduce financial costs [11]